Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Endo International plc (NASDAQ: ENDP) has agreed to pay $50 million to resolve lawsuits by New York state and two of its largest counties related to the sale and marketing of opioids. Endo said the settlement includes no admission of wrongdoing by Endo or its subsidiaries.

Endo Shares Move Higher On Settlement Of New York State Opioid Cases

DUBLIN, Sept. 9, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc., have settled three consolidated cases pending in Suffolk County Supreme Court in the State of New York:  County of Suffolk v.

Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation

DUBLIN, Aug. 31, 2021 /PRNewswire/ -- Endo International plc ("Endo") (NASDAQ: ENDP) today commented on the United States District Court for the District of Delaware's non-infringement ruling in favor of Eagle Pharmaceuticals Inc. ("Eagle") in patent litigation regarding Eagle's abbreviated new drug application, or ANDA, for Par Sterile Products, LLC's VASOSTRICT® product.  Because the court found non-infringement of Endo's patents by Eagle's proposed product, it did not rule on the patents' validity.

Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 35% at $2.31 following a Wall Street Journal report indicating the company has engaged a restructuring adviser to explore options amid opioid-related lawsuits. Endo International shares were trading higher during the July 22nd session after the company announced it reached an agreement in principle to pay $35 million to settle an ongoing Opioid case in Tennessee.

What's Up With Endo International's Stock Getting Hammered?

The drugmaker could be evaluating financial restructuring options.

Why Endo Stock Is Crashing Today

Endo International PLC (ENDP) CEO Blaise Coleman on Q2 2021 Results - Earnings Call Transcript

Endo (ENDP) delivered earnings and revenue surprises of 54.76% and 8.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q2 Earnings and Revenues Beat Estimates

DUBLIN, Aug. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2021. "Our second-quarter 2021 results reflect strong sequential growth in our Branded Pharmaceuticals segment driven by XIAFLEX®, and better than expected performance of our Sterile Injectables and Generic Pharmaceuticals segments," said Blaise Coleman, President and Chief Executive Officer at Endo.

Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance

DUBLIN, Aug. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P.

Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Endo International (ENDP) Q2 Earnings Expected to Decline

DUBLIN, July 29, 2021 /PRNewswire/ -- Encouraging Phase I safety and tolerability results of CCH as a nonsurgical treatment of plantar fibromatosis Research to continue to Phase II; retreatment phase also is ongoing in eligible patients Endo International plc (NASDAQ:ENDP) announced today initial results from a Phase I study (EN3835–105) evaluating collagenase clostridium histolyticum (CCH) for the treatment of plantar fibromatosis. The data are being presented as an e-poster at the American Podiatric Medical Association Annual Scientific Meeting, The National, in Denver, July 29–August 1.

Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting

The stock price of Endo International PLC (NASDAQ: ENDP) increased by 3.8% today. This is why it happened.

ENDP Stock Increased 3.8%: Why It Happened

Citius Pharmaceuticals

There's a reason that so many investors like Reddit penny stocks; here's 3 for your list The post Best Reddit Penny Stocks to Buy in August? 3 For Your List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Reddit Penny Stocks to Buy in August? 3 For Your List

Endo International PLC (NASDAQ: ENDP) shares are trading higher Thursday afternoon after the company announced it has reached an agreement in principle to pay $35 million to settle an ongoing Opioid case in Tennessee. Endo International is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology and bariatrics.

Why Endo Shares Are Surging Higher Today

DUBLIN, July 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") have reached an agreement in principle to settle an opioid-related case originally captioned as Staubus, et al. v. Purdue Pharma, L.P.

Endo Announces Agreement in Principle to Settle Tennessee State Court Case

The possibility of a settlement in an opioid lawsuit the company is fighting in Tennessee raised investors' hopes.

Why Shares of Endo Pharamecuticals Are Soaring Today

The stock price of Endo International PLC (NASDAQ: ENDP) increased by over 27% during intraday trading. This is why it happened.

ENDP Stock Increased Over 27% Intraday: Why It Happened

The drugmaker could be close to reaching a settlement in Tennessee over its opioid drugs.

Why Endo Stock Is Soaring Today

DUBLIN, July 15, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced the issuance of several orders by the Tennessee Supreme Court and the Tennessee Court of Appeals regarding a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in Case No. C-41916, originally captioned as Staubus, et al.

Endo Comments on Tennessee Appeals Court Orders

Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

AbbVie

AmerisourceBergen

Cardinal Health

CVS Health

Johnson & Johnson

McKesson

Rite Aid

Teva Pharmaceutical

Walgreens

Walmart

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors, urging them to hold the companies liable. Jayne Conroy, representing Suffolk County, also said that the drug distributors - AmerisourceBergen Corp (NYSE: ABC), Cardinal Health Inc (NYSE: CAH), and McKesson Corp (NYSE: MCK) failed to report suspicious opioid orders as required.

New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid

DUBLIN, June 24, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its second–quarter 2021 financial results on August 5, 2021 after the U.S. financial markets close and members of its senior management team will host a conference call and webcast on August 6, 2021 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 9749734.

Endo to Announce Second Quarter 2021 Financial Results

DUBLIN , June 24, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during Cosmetic Bootcamp Summer Event. This data will be highlighted in three e-posters that will be available during the virtual and in-person meeting taking place in Aspen, CO, June 24–27, 2021.

Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021

DUBLIN, June 11, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, "Endo") in  Case No. C-41916, originally captioned as Staubus, et al.

News for Endo International Stock (ENDP)